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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of marine-derived n-3 fatty acids administration on functional outcomes and dependence in people with stroke.
B A C K G R O U N D
Description of the condition
Stroke, defined as the acute onset of a persistent focal neurolog-
ical deficit related to a specific cerebrovascular location (Barret
2013), is a general term that comprises different diseases involv-
ing blood vessels supplying the brain (Caplan 2006). Strokes can
be broadly classified as haemorrhagic or ischaemic. Haemorrhagic
stroke comprises mainly intracerebral haemorrhage (ICH) and
subarachnoid haemorrhage (SAH), which account for 5% to 15%,
and 5%, respectively, of all acute strokes (Barret 2013). In an is-
chaemic stroke on the other hand, there is a lack of blood sup-
ply for normal functioning of the brain tissue; the three major
categories are thrombosis, embolism, and systemic hypoperfusion
(Caplan 2006). From the more than 790,000 cases of new or re-
current strokes registered each year in the USA, up to 87% are
ischaemic (Mozaffarian 2016). Transient ischaemic attacks (TIAs)
are temporary disruptions in circulation to a part of the brain
(Caplan 2006). Two regions are found within the infarct in is-
chaemic stroke: the necrotic core, which is irreversibly injured due
to rapid cell death; and the ischaemic penumbra, an area that sur-
rounds the core and where neurons remain potentially salvageable
(Blondeau 2016; Yao 2013). The penumbra has a life span of only
a few hours and, during this period, reperfusion or neuroprotec-
tive therapy is needed to prevent irreversible damage (Yao 2013).
In response to stroke, physiological and structural changes take
place in neuronal circuits surrounding the infarct in order to stim-
ulate neural repair. These include the formation of new connec-
tions in cortical areas (termed axonal sprouting, which is also influ-
enced by neurorehabilitation), neural progenitor responses (neu-
rogenesis and gliogenesis), and changes in neuronal excitability in
peri-infarct tissue (Carmichael 2016). However, reperfusion af-
ter ischaemia can, paradoxically, result in enhanced tissue injury
(Eltzschig 2011). Therefore, neuroprotectants that potentially at-
tenuate damage related to reperfusion injury are also needed. In
addition, itmust be taken into account that theoretically beneficial
compounds may have adverse effects during the recovery phase,
given that stability and protection is required in the acute phase,
whereas neuronal plasticity is needed during the following stages
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(Carmichael 2016). The timing of intervention is critical for opti-
mal recovery after stroke: alteplase is effective when administered
within 4.5 hours from stroke ictus, while clot retrieval is beneficial
up to 7.3 hours (Saver 2016). Due to public awareness campaigns,
more people are arriving in emergency departments early after the
event, but other than intravenous thrombolysis or thrombectomy,
there are no evidence-based neuroprotective agents currently avail-
able. In contrast with other cardiovascular events, stroke tends to
leave permanent sequelae and generally requires long-term reha-
bilitation and specialised care (Tanaka 2008). In 2013, there were
more than 25million stroke survivors worldwide and global stroke
burden is increasing (Feigin 2015). For these reasons, the need to
explore therapeutic options to ameliorate the acute insult remains.
Description of the intervention
High oily fish intake has been related to a reduced mortality from
coronary (Hu 2002; Kris-Etherton 2002) and ischaemic heart dis-
ease (Zhang 1999) in both sexes. Epidemiological studies have re-
ported mixed results regarding stroke, while some observed an in-
verse relationship betweenfish intake and stroke incidence (Gillum
1996; Iso 2001;Keli 1994) andmortality (Hu 2002;Zhang 1999),
others have found no significant effect (Morris 1995; Orencia
1996). Given the nature of observational studies, potential con-
founding factors - such as lifestyle and other dietary compounds
- need to be taken into account when assessing the evidence. As
oily fish is an important source of omega-3 (n-3) polyunsaturated
fatty acids (PUFAs), mainly eicosapentaenoic acid (EPA) and do-
cosahexaenoic acid (DHA) (Saravanan 2010), potential effects of
fish intake on cardiovascular diseases have been attributed to these
n-3 PUFAs.
EPA and DHA are synthesised by marine algae and are concen-
trated in fish and marine oils, in contrast with inland vegetal n-3
fatty acids sources, which contain primarily alpha-linolenic acid
(ALA) (Bradbury 2011; Valenzuela 2009). EPA and DHA com-
prise approximately 30% of the fatty acids present in fish oil; how-
ever, their proportion varies according to the type of fish (Calder
2012a). Presently, apart from seafood, these fatty acids can be
found in supplements of fish oil, fish liver oil, krill oil, and also
as pharmaceutical grade ethyl ester formulations (Calder 2009).
Availability of n-3 PUFAs has allowed pharmacological interven-
tion trials using highly purified fatty acids concurrently with food-
based trials (Yokoyama 2007). Currentmarine-derived n-3 PUFAs
intake recommendations from different health bodies in Western
countries are around 500 mg per day of combined EPA and DHA,
the equivalent of two oily fish meals per week (Kris-Etherton
2009).
EPA comprises 20 carbon atoms and five double bonds and it is
required for production of eicosanoids (Bradbury 2011). EPA, in
its ethyl ester form, has been approved in Japan as a treatment for
hyperlipidaemia and peripheral artery disease (Yokoyama 2007).
Furthermore, it has been shown to reduce the recurrence of stroke
in a Japanese hypercholesterolaemic population (Tanaka 2008).
DHA, with the longest side chain (22 carbon atoms) and six dou-
ble bonds, is concentrated mainly in the sn-2 position of the phos-
pholipids in cellular membranes (Valenzuela 2013), and it confers
particular structural and functional features to them, especially in
the retina and in the neuronal synapses of the brain (Bradbury
2011). DHA is essential for normal brain growth and cognitive
function (Bazan 2009): dietary supplies are required for mem-
brane replacement, maintaining synaptic integrity and function,
gene regulation and synthesis of docosanoids and neuroprotectins
(Bazinet 2014). DHA also plays a critical role in neuronal survival
and is a potent modulator of brain inflammation (Belayev 2011).
DHA therefore has potential roles in prevention and attenuation
of ischaemic injury, and also in facilitating repair and neuroplas-
ticity after stroke (Eady 2012).
How the intervention might work
Increasing intakes of n-3 fatty acids from fatty fish could positively
influence the prevention of stroke (Ikeya 2013). Furthermore, in
people with acute ischaemic stroke, a low serum n-3/n-6 PUFAs
ratio on admission has been shown to predict neurological deteri-
oration (Suda 2013). In patients on a low-dose statin therapy, ad-
ministration of EPA reduced the risk of a recurrent stroke (Tanaka
2008). Marine n-3 fatty acids are suggested to reduce inflamma-
tion, improve endothelial activity, and decrease platelet aggrega-
tion (Calder 2012a; Calder 2012b). N-3 PUFAs’ antithrombotic
effects include reducing thrombin formation, decreasing oxidative
stress (Gajos 2011), and increasing plaque stability (Thies 2003).
Recent findings from animal models showed that unesterified
DHA injection or infusion with fish oil within three hours af-
ter brain ischaemia reduced total infarct volume by 40% in rats
(Belayev 2009), and by 21% in mice (Zhang 2014), compared
to placebo; and significantly improved functional outcome af-
ter cerebral ischaemia in both models. In a rat model, DHA ad-
ministration up to five hours after focal ischaemia increased neu-
robehavioural recovery, reduced brain infarction and oedema, and
activated neuroprotectin D1 (NPD1) synthesis in the penum-
bra (Belayev 2011). NPD1 is part of a family of lipid mediators
synthesised from both EPA (E-series resolvins) and DHA (D-se-
ries resolvins and protectins) which stimulates cell-protecting and
pro-survival signalling (Belayev 2011) and seems to have a role
in neuroprotection (Calder 2012a). NPD1 suppresses apoptosis
(Bazan 2005) and promotes neurogenesis (Eady 2014). Addition-
ally, DHA exerts an anti-inflammatory effect during ischaemic
injury through the attenuation of microglia activation in both
young and aged ratmodels (Belayev 2011; Eady 2014;Hong 2014;
Zendedel 2015).
N-3 PUFAs treatment in rats also attenuated the death of both
neurons and astrocytes, with the latter being essential for neuronal
survival (Belayev 2011; Zendedel 2015). In mice supplemented
with n-3 PUFAs-enriched fish oil for three months before and
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up to one month after stroke, n-3 PUFAs stimulated the expres-
sion of angiopoietin (Ang) 1 and Ang 2, improved the migration
and survival of neuroblasts, preserved myelin integrity and pro-
moted oligodendrogenesis after ischaemia, facilitating therefore
the recovery of white matter and neurological functions (Zhang
2015). Transgenic fat-1 mice bred to overproduce n-3 PUFAs
have been shown to have long-term behavioural and histological
protection against transient focal cerebral ischaemia, exhibiting
improvements in revascularization and angiogenesis compared to
wild-type littermates (Wang 2014). These results, taken together,
suggest that n-3 PUFAs may be beneficial not only in the acute
phase but also for long-term functional recovery after cerebral is-
chaemia.
With respect to the risk of haemorrhagic stroke, evidence assessing
the impact of n-3 PUFAs intake shows conflicting results. Early
epidemiological studies in Greenlandic Eskimos (or Inuit) ob-
served a relationship between increased fish intake and incidence
of haemorrhagic stroke (Dyerberg 1979; Ostergaard Kristensen
1983). This effect is likely due to the EPA component of fish
oil, which inhibits platelet aggregation (Jakubowski 1979). How-
ever, an augmented incidence of cerebral haemorrhage was not
observed in later studies in women with high consumption of
fish and n-3 PUFAs (Iso 2001), nor in patients treated with EPA
(Nakase 2015).
Why it is important to do this review
Given that stroke is one of the main causes of long-term disabil-
ity worldwide (Mozaffarian 2016), it is critical to examine the es-
tablished and potential approaches to protecting the brain dur-
ing the crucial period of damage and recovery. If n-3 supplements
were shown to reduce cerebral ischaemia severity or improve re-
covery without increasing the risk of cerebral haemorrhage, this
would provide a safe, inexpensive, and simple intervention which
is easily implementable. Some studies looking at n-3 supplementa-
tion and human stroke have been reported. One non-randomised
study of stroke patients already taking EPA found no increased
risk of haemorrhage but was underpowered for recurrent events
(Nakase 2015), while a sub-analysis of the Japan EPA Lipid In-
tervention Study (JELIS) found reduced risk of recurrent stroke
in patients also taking low-dose statin (Tanaka 2008). A study us-
ing a guideline-recommended moderate dose of fish oil supple-
ment (0.7 g DHA daily) or placebo on cardiovascular biomarkers,
mood- and health-related quality of life in patients with ischaemic
stroke found no effect after 12 weeks’ supplementation (Poppitt
2009). Heterogeneity in results might be related to variation in
doses or intervention time, different pathophysiologies of the clin-
ical outcomes (Mozaffarian 2006), and the potential oxidation of
the fish oils (Poppitt 2009). Also, the effect of n-3 fatty acids ad-
ministration is likely to differ by type of stroke: therefore assessing
their impact on total stroke risk might underestimate the strength
of the real association with a specific type of stroke (Kris-Etherton
2002; Zhang 1999). No systematic review looking specifically at
the effect of n-3 PUFAs as a treatment for stroke has been pub-
lished. This Cochrane Review will combine and summarise the
available outcome evidence from human randomised studies of
marine-derived n-3 PUFAs administration after stroke.
O B J E C T I V E S
To assess the effects of marine-derived n-3 fatty acids adminis-
tration on functional outcomes and dependence in people with
stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) of marine-
derived n-3 fatty acids administration after stroke onset, versus
placebo or open control (no placebo), regardless of time lapse
between onset and intervention, language, and blinding design.
We will exclude quasi-randomised, non-randomised, and obser-
vational studies.
Types of participants
We will include all participants with a diagnosis of stroke (includ-
ing TIA) on the basis of clinical examination findings, diagnostic
test results, or according to the definitions used by researchers to
enrol participants in their studies, regardless of severity, comorbidi-
ties, age, gender, and phase of the disease (from acute to chronic).
We will include trials with mixed populations in the meta-analysis
when they meet our inclusion criteria and separate data for stroke
patients are available.
Types of interventions
Wewill include trials comparing administration of marine-derived
n-3 fatty acids regardless of duration, dosage, route of administra-
tion, or type (fatty acids supplements, marine oils or fish intake)
with placebo or no intervention. Eligible interventions include but
are not limited to: fish oil, krill oil, microalgae oil, cod liver oil,
other marine oils, n-3 fatty acids ethyl esters, and consumption of
fish (such as salmon, mackerel, tuna, trout, sprat, pilchard, her-
ring, sardine, swordfish).
We will exclude trials in which only one of the groups (treatment
or control) received another active therapy. However, we will in-
clude trials where the addition of marine-derived n-3 fatty acids
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to another treatment is compared to the other treatment alone,
therefore assessing the effect of marine-derived n-3 fatty acids.
Types of outcome measures
Primary outcomes
The primary outcome will be efficacy (functional outcome or dis-
ability/dependency) for the latest time point of assessment, using
a validated scale (e.g. modified Rankin Scale (mRS); Barthel in-
dex (BI); or change in National Institutes of Health Stroke Scale
(NIHSS)). For studies using multiple scales, we will select the one
with the largest amount of data available or, in the case of equal
amounts of data, the one reported first in the study.
Secondary outcomes
We will assess the secondary outcomes as follows: after a short
follow-up (up to three months), and after a longer follow-up (over
three months).
• Vascular-related death.
• Recurrent events: fatal or non-fatal (same type of stroke, i.e.
ischaemic or haemorrhagic).
• Incidence of different type of stroke (ischaemic or
haemorrhagic): fatal or non-fatal.
• Adverse events: nausea, vomiting, allergic reaction, or other
serious adverse events associated with the intervention.
• Quality of life (scales defined by authors).
• Mood (scales defined by authors).
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module. We will search for trials in all languages and arrange for
the translation of relevant articles where necessary.
Electronic searches
We will search the Cochrane Stroke Group trials register and the
following electronic databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL; latest issue) in the Cochrane Library.
• MEDLINE Ovid (from 1948) (Appendix 1).
• Embase Ovid (from 1980).
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; from 1982).
• Science Citation Index Expanded - Web of Science (SCI-
EXPANDED).
• Conference Proceedings Citation Index- Science - Web of
Science (CPCI-S).
• BIOSIS Citation Index.
We developed the MEDLINE search strategy (Appendix 1) with
the help of the Cochrane Stroke Group Information Specialist and
will adapt it for the other databases.
We will also search the following ongoing trials registers.
• US National Institutes of Health Ongoing Trials Register (
clinicaltrials.gov)
• Stroke Trials Registry (strokecenter.org/trials/)
• ISCRTN Registry (isrctn.com/)
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (who.int/ictrp/en/)
Searching other resources
In order to identify other published, unpublished and ongoing
studies we will:
• check the bibliographies of included studies and any
relevant systematic reviews identified for further references to
relevant trials;
• use the Science Citation Index Reference Search for forward
tracking of included trials;
• contact researchers in the field to obtain additional
information on relevant trials;
• contact original authors for clarification and further data if
trial reports are unclear.
Data collection and analysis
Selection of studies
Two review authors (CGAC, MJM) will independently screen
titles and abstracts of the references obtained as a result of our
searching activities and will exclude obviously irrelevant reports.
We will retrieve the full-text articles for the remaining references
and two review authors (CGAC, MJM) will independently screen
the full-text articles and identify studies for inclusion, and identify
and record reasons for exclusion of the ineligible studies. We will
resolve any disagreements through discussion or, if required, we
will consult a third author (MRM).Wewill collatemultiple reports
of the same study so that each study, not each reference, is the unit
of interest in the review. We will record the selection process and
complete a PRISMA flow diagram.
Data extraction and management
Two review authors (CGAC, FT) will independently extract data
from included studies. Information extracted will include study
settings, time frame, type of event, type of intervention, as well
as dose and mode of delivery, participants’ characteristics, dietary
information, outcomes reported, and trials authors’ definitions.
Discrepancies among authors will be resolved by consultation with
a third author (MJM).
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Assessment of risk of bias in included studies
Two review authors (CGAC, FT) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (MRM). We will assess the risk of bias according
to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We will grade the risk of bias for each domain as high, low or
unclear and provide information from the study report together
with a justification for our judgment in the ’Risk of bias’ tables.
Measures of treatment effect
For continuous outcomes we will calculate the mean difference
(MD)with 95%confidence intervals (CI) for datameasured in the
sameway between trials; and standardizedmean difference (SMD)
with 95% CI when different scales were used for measurement.
For binary outcomes, we will calculate the risk ratios (RR) with
95% CI.
Unit of analysis issues
We anticipate that inmost trials the unit of analysis will be individ-
ual participants. For studies where there is more than one follow-
up period, we will include the longest period recorded to extract
outcome data. For non-fatal recurrent events, we will only record
the first event of each participant. If we identify studies with non-
standard designs (e.g. cross-over trials, cluster randomised studies)
we will consider their inclusion, following the guidance in Chap-
ter 16 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011).
Dealing with missing data
We will contact the authors to request any missing data. If unsuc-
cessful, we will consider the guidelines from the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011) for data
imputation.
Assessment of heterogeneity
We will use the I² statistic to measure heterogeneity among the
trials in each analysis, with a value above 50% indicating substan-
tial heterogeneity. If we identify substantial heterogeneity, we will
explore the reasons and identify if there are clinical or method-
ological explanations for differences in treatment effects between
studies.
Assessment of reporting biases
If possible, we will use funnel plots for all the outcomes to assess
reporting bias. If we include fewer than 10 trials in this systematic
review, we will assess reporting bias qualitatively on the basis of
characteristics of included trials.
Data synthesis
Where we consider that studies can be combined, we will conduct
a random-effects model meta-analysis by pooling the appropriate
data using Review Manager 5 (Review Manager 2014). If a meta-
analysis is not possible, we will summarize the results in a narrative
manner, including text, figures and tables.
GRADE and ’Summary of findings’ tables
We will create ’Summary of findings’ tables (see Table 1 and Table
2 below) to compare the administration of marine-derived n-3
fatty acids versus placebo or no intervention after both a short
(up to three months) and a longer (over three months) follow-up,
using the following outcomes: efficacy (activities of daily living
as measured using mRS or Barthel Index, or neurological impair-
ment measured as change in NIHSS), vascular-related death, re-
current events, incidence of different type of stroke, adverse events,
quality of life, and mood. We will use the five GRADE consid-
erations (study limitations, consistency of effect, imprecision, in-
directness and publication bias) to assess the quality of a body
of evidence as it relates to the studies that contribute data to the
meta-analyses for the prespecified outcomes (Atkins 2004). We
will use methods and recommendations described in Section 8.5
and Chapter 12 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) using GRADEproGDT software
(GRADEproGDT 2015).We will justify all decisions to down- or
up-grade the quality of studies using footnotes, and we will make
comments to aid the reader’s understanding of the review where
necessary.
Subgroup analysis and investigation of heterogeneity
If appropriate data are available, we plan to carry out subgroup
analyses based on: type of stroke (ischaemic or haemorrhagic),
dose, type of intervention (fatty acids supplements, marine oils
or fish intake), length of intervention (up to three months and
over three months), and initial time of intervention (up to three
months and over three months from event onset).
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Sensitivity analysis
If we have a sufficient number of studies wewill perform sensitivity
analyses by: excluding the trials with overall high risk of bias, and
excluding studies with substantial missing data.
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A D D I T I O N A L T A B L E S
Table 1. Summary of findings template: short follow-up
Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy for stroke. Follow-up of 3
months or sooner
Patient or population: people with stroke
Setting: hospital, outpatient, community or home
Intervention: marine-derived n-3 fatty acids therapy
Comparison: no marine-derived n-3 fatty acids therapy
Outcomes Anticipated absolute effects
(95% CI)
Relative effect
(95% CI)
of participants
(studies)
Quality
of the evidence
(GRADE)
Comments
Risk with noma-
rine-derived n-3
fatty acids ther-
Risk with ma-
rine-derived n-3
fatty acids ther-
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Table 1. Summary of findings template: short follow-up (Continued)
apy apy
Efficacy
Vascular-related
death
Recurrent events
Incidence of dif-
ferent type of
stroke
Adverse events
Quality of life
Mood
CI: confidence interval
Table 2. Summary of findings template: longer follow-up
Marine-derived n-3 fatty acids therapy compared to no marine-derived n-3 fatty acids therapy for stroke. Follow-up longer
than 3 months
Patient or population: people with stroke
Setting: hospital, outpatient, community or home
Intervention: marine-derived n-3 fatty acids therapy
Comparison: no marine-derived n-3 fatty acids therapy
Outcomes Anticipated absolute effects
(95% CI)
Relative effect
(95% CI)
of participants
(studies)
Quality
of the evidence
(GRADE)
Comments
Risk with noma-
rine-derived n-3
fatty acids ther-
apy
Risk with ma-
rine-derived n-3
fatty acids ther-
apy
Efficacy
Vascular-related
death
Recurrent events
Incidence of dif-
ferent type of
stroke
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Table 2. Summary of findings template: longer follow-up (Continued)
Adverse events
Quality of life
Mood
CI: confidence interval
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
cerebral small vessel diseases/ or exp intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial
hemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying)
adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial
or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h?
ematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/ or exp Gait Disorders, Neurologic/
6. (hemipleg$ or hemipar$ or paresis or paraparesis or paretic).tw.
7. or/1-6
8. exp fish oils/ or fatty acids/ or fatty acids, omega-3/ or docosahexaenoic acids/ or eicosapentaenoic acid/
9. exp Fishes/ or seafood/ or fish products/ or shellfish/ or Dietary Fats/
10. (((fish$ or cod or mackerel or kipper$ or pilchards or tuna or trout or sprat$ or salmon or herring or crab or whitebait or swordfish
or sardine$ or krill or microalgae or marine) adj3 (oil$ or fat$ or acid$ or omega-3 or omega3 or omega 3 or n-3 or polyunsaturat$))
or PUFA$).tw.
11. ((Docosahexaenoic or eicosapentaenoic or icosapentaenoic) adj3 acid$).tw.
12. (EPA or DHA).tw.
13. or/8-12
14. Randomized Controlled Trials as Topic/
15. Random Allocation/
16. Controlled Clinical Trials as Topic/
17. control groups/
18. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
19. double-blind method/
20. single-blind method/
21. Placebos/
22. placebo effect/
23. cross-over studies/
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24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
27. (random$ or RCT or RCTs).tw.
28. (controlled adj5 (trial$ or stud$)).tw.
29. (clinical$ adj5 trial$).tw.
30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
31. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
32. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
33. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
34. (cross-over or cross over or crossover).tw.
35. (placebo$ or sham).tw.
36. trial.ti.
37. (assign$ or allocat$).tw.
38. controls.tw.
39. or/14-38
40. 7 and 13 and 39
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